Beam Therapeutics Inc
Performance History
| Key Stats | |
|---|---|
| Open | $29.05 |
| Prev. Close | $28.59 |
| EPS | -4.17 |
| Dividend | $0.00 |
| Next Earnings Date | Aug 8, 2023 |
| Dividend Yield % | - |
| Market Cap | $2.28B |
| PE Ratio | - |
| low | high | |
|---|---|---|
| Day Range | 27.65 | 29.51 |
| 52 Week Range | 16.95 | 51.60 |
| Ratios | |
|---|---|
| P/B Ratio | 2.99 |
| Revenue | $81.55M |
| Operating M. % | -629.72% |
| Earnings | -$313.67M |
| Earnings Growth % | 8.82% |
| EBITDA Margin % | -465.62% |
| ROE % | -38.14% |
| EPS | -4.17 |
Score Breakdown
All Score (63 / 100) is to help users identify stocks that trade at a low value relative to their fundamentals. Suitable for value investors such as Warren Buffet.
| BEAM | Market | |
|---|---|---|
| Value | 41 | 42 |
| Quality | 60 | 46 |
| Ownership | 65 | 39 |
| Growth | 58 | 44 |
| Dividends | - | 32 |
All Score (63 / 100) is to help users identify stocks that trade at a low value relative to their fundamentals. Suitable for value investors such as Warren Buffet.
Financial Forecast
AI Price Prediction
Analyst Ratings
Correlated Companies
About Beam Therapeutics Inc (BEAM)
Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 and BEAM-102 for the treatment of sickle cell disease beta thalassemia; BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease; and the Institute of Molecular and Clinical Ophthalmology Basel for treatment of impaired vision and blindness. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.
- ISN
- -
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. John M. Evans M.B.A.
- Headquarters
- Cambridge
- Employees
- 532
Keep an eye on Beam Therapeutics Inc
Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.
News
Sign up for our newsletter
Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.